trastuzumab deruxtecan + pembrolizumab + fluorouracil

This is an investigational **combination therapy** consisting of **trastuzumab deruxtecan** (a HER2-directed antibody-drug conjugate), **pembrolizumab** (an anti–PD-1 checkpoint inhibitor), and **fluorouracil** (a thymidylate synthase inhibitor classified as a cytotoxic chemotherapy). The regimen is under clinical development primarily for the first-line treatment of **HER2-positive gastric cancer, gastroesophageal junction adenocarcinoma, and esophageal adenocarcinoma**. Trastuzumab deruxtecan targets HER2-expressing cells delivering a cytotoxic topoisomerase I inhibitor payload, pembrolizumab blocks the PD-1 pathway mediating immune checkpoint inhibition, and fluorouracil interferes with DNA synthesis in rapidly dividing cells. Developed as an extension to the DESTINY-Gastric03 study, the triplet regimen is designed to combine targeted therapy, immunotherapy, and chemotherapy[1][6].

Brand names

Enhertu (trastuzumab deruxtecan)Keytruda (pembrolizumab)None (combination as a unit does not have a unique brand name)

Other names

T-DXd + pembrolizumab + fluorouracilTrastuzumab deruxtecan + pembrolizumab + 5-FUTrastuzumab deruxtecan + pembrolizumab + fluoropyrimidine